• Health Care M&A Deals, September 18, 2020

    The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal... Read More »
  • MetLife Acquires Versant Health

    MetLife, Inc. (NYSE: MET) has entered the healthcare M&A market. Last week, the company announced the acquisition of Versant Health, the parent company of Davis Vision and Superior Vision, two major vision care and insurance brands with a combined 35 million members. Centerbridge Partners and an investor group including FFL Partners are... Read More »
  • CloudMD Expands Patient Engagement Portfolio

    CloudMD Software & Services Inc. (OTCMKTS: DOCRF) just keeps rolling out new deals and acquisitions. The company has been very active this year, with six acquisitions on the books so far across various sectors, according to search results in our Deal Search Online database. Last week, CloudMD acquired Toronto-based iMD Health Global Corp. for... Read More »
  • Trulieve Cannabis Boosts Its Market Reach

    Trulieve Cannabis Corp. (OTC: TCNNF), a vertically integrated “seed-to-sale” company and the first licensed medical cannabis company in the state of Florida, announced two new transactions last week. M&A activity in the medical marijuana market has been quiet throughout 2020 and 2019, after experiencing somewhat of a boom in 2018,... Read More »
  • A Busy Week for Home Health & Hospice Deals

    It was a busy week for home health & hospice (HH&H) transactions. Results from our Deal Search Online database show there were four announced last week alone, half of September’s total so far. Half of the deals were completed by private equity-backed companies, which highlights the continued interest in HH&H from PE firms. Jet... Read More »

PE Firms Line Up for Pharmaceutical Targets

Although pharmaceutical M&A has declined sharply over the past year, there has been an uptick in financial buyer activity in the sector in the first eight months of 2017. We don’t typically see a lot of financial buyers in this space, since they are easily outbid by strategic buyers that have the advantage of easy access to capital and cost synergies. Also, private equity buyers have been flocking to acquire “healthcare-lite” targets, such as eHealth or contract research organizations, in the past 12 months, largely to avoid potential regulatory and reimbursement roadblocks that come with a new administration. Pharmaceutical M&A is down 65% (only 55 deals) compared with the 156... Read More »